Paper Details

  1. Home
  2. Paper Details

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.

Author: BaoJiandong, ChenGuang, ChenWenxin, FuWei, GaoZairong, HouZhiguo, JingShanghua, LiLinfa, LiShaohua, LiZhiyong, LiangJun, LinChenghe, LinYansong, MaQingjie, MiaoWeibing, QinShukui, RenYuan, SangYaxiong, XuHuiqin, YangHui, ZhangHong, ZhangQing, ZhangYifan, ZhaoXinming, ZhouXianfeng

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Apatinib, a VEGFR-2 inhibitor, showed significant clinical benefits in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) in a phase 3 trial. The drug demonstrated prolonged progression-free survival (PFS) and overall survival with a manageable safety profile.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) have a poor prognosis and limited treatment options. OBJECTIVE: To assess the efficacy and safety of apatinib, a highly selective vascular endothelial growth factor (VEGFR-2) inhibitor, in patients with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678901/

データ提供：米国国立医学図書館（NLM）

Apatinib: A New Oasis in the Desert of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a challenging condition with limited treatment options. This research investigates the efficacy and safety of apatinib, a highly selective vascular endothelial growth factor (VEGFR-2) inhibitor, in patients with progressive locally advanced or metastatic RAIR-DTC. The authors conducted a randomized, double-blind, placebo-controlled phase 3 trial (REALITY) to evaluate the effectiveness of apatinib.

Apatinib: A Promising New Hope for RAIR-DTC

The REALITY trial demonstrates the significant clinical benefits of apatinib in treating patients with progressive locally advanced or metastatic RAIR-DTC. Apatinib significantly prolonged progression-free survival and overall survival while maintaining a manageable safety profile. These findings present a crucial breakthrough in the treatment of this challenging disease.

Navigating the Desert of RAIR-DTC: Apatinib Offers a Ray of Hope

This research provides a beacon of hope for patients with RAIR-DTC, offering a new and effective treatment option. It highlights the importance of continued research and innovation in developing targeted therapies for difficult-to-treat cancers. The success of apatinib underscores the potential of personalized medicine in achieving better outcomes for patients.

Dr. Camel's Conclusion

The desert of RAIR-DTC can be a lonely and daunting landscape. Apatinib offers a refreshing oasis, providing a promising new treatment that could significantly improve the lives of patients. This research is a testament to the power of persistence and ingenuity in the fight against cancer.

Date :
  1. Date Completed 2022-03-14
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34913959

DOI: Digital Object Identifier

PMC8678901

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.